News

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 ...
Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...
Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for completion by October.
Pfizer has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...
The enrolment for phase III clinical trials of India's first dengue vaccine, DengiAll, is expected to be completed by October ...
The one-shot vaccine, developed by Panacea Biotec and branded as DengiAll, is being tested through a multi-centre, double-blind, randomised, placebo-controlled trial.
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
MAXONA Pharmaceuticals announced the formation of its Scientific Advisory Board (SAB) and the successful completion of its ...